Health Canada Approves Dexcom G7 for Pregnancy Use

The approval extends the myLoop automated insulin delivery system to pregnant women with type 1 diabetes in Canada.

Updated on Nov. 9, 2026 in Diabetes

Photograph of a small round glucose sensor and a plain insulin pump resting on a pale wooden table in soft window light. — Health Canada approved the Dexcom G7 sensor for use with the myLoop automated insulin delivery system for pregnant women with type 1 diabetes. AI Illustration. Upload story photo >

Health Canada has approved the Dexcom G7 Continuous Glucose Monitoring System for use with myLoop, powered by CamAPS FX, during pregnancy. The system is the only automated insulin delivery option in Canada approved specifically for pregnant users.

Why it matters

Insulin needs can shift considerably during pregnancy while glucose targets remain tight, making close monitoring and adaptive dosing important. The approval gives Canadian users in this situation an additional sensor option within an automated system.

The AiDAPT randomized controlled trial of 124 pregnant women with type 1 diabetes, conducted across nine clinics, found CamAPS FX users spent 10.5 percentage points more time in the pregnancy glucose target range than those on standard care. The extraction does not specify availability timing, so the practical rollout remains unclear.

The players

Health Canada

Health Canada is the federal department responsible for regulating health products, drugs and medical devices in Canada.

Dexcom

Dexcom is a United States medical technology company that manufactures continuous glucose monitoring systems.

CamDiab Ltd.

CamDiab Ltd. is the developer of the CamAPS FX app and algorithm that powers the myLoop automated insulin delivery system.

mylife Diabetes Care

mylife Diabetes Care is a Switzerland-based company that works with CamDiab and Dexcom on the myLoop system.

The details

Health Canada approved use of the Dexcom G7 sensor with myLoop, which pairs the YpsoPump insulin pump with the CamAPS FX app and algorithm developed by CamDiab Ltd. The Dexcom G7 was added through technical collaboration between CamDiab and Dexcom, working with mylife Diabetes Care, and the system uses an adaptive algorithm that adjusts insulin delivery continuously. The AiDAPT trial also found lower mean glucose and HbA1c levels among CamAPS FX users and no added risk of hypoglycemia.

March 2025: myLoop powered by CamAPS FX debuted in Canada as the country's first smartphone-based automated insulin delivery system.
November 9, 2026: Health Canada approval of the Dexcom G7 with myLoop was announced.

Regulatory Landscape

The approval extends the myLoop system, which Canada launched in March 2025 as its first smartphone-based automated insulin delivery option, into the pregnancy indication supported by the AiDAPT trial published in The New England Journal of Medicine. It follows Health Canada's earlier authorization of the system and adds a new sensor option within that already-approved framework.

For pregnant Canadians with type 1 diabetes, the approval adds the Dexcom G7 as a sensor option within an automated insulin delivery system. Availability is subject to launch timing and local market conditions, so patients should confirm with their care team when the option is accessible.

The takeaway

Automated insulin delivery systems are increasingly being adapted for high-stakes clinical situations such as pregnancy, where glucose targets are tight and insulin needs change quickly. Patients with type 1 diabetes who are pregnant or planning pregnancy should discuss available monitoring and delivery options with their clinicians.